<?xml version="1.0" encoding="UTF-8"?>
<p>Given the broad antiviral activity of favipiravir, we also evaluated 
 <italic>in vitro</italic> its efficacy against Zika and Marburg viruses and reported antiviral EC
 <sub>50</sub> of 6.5 and 6.8 µg/mL, respectively.
 <xref rid="psp412510-bib-0007" ref-type="ref">
  <sup>7</sup>
 </xref>, 
 <xref rid="psp412510-bib-0008" ref-type="ref">
  <sup>8</sup>
 </xref> Interestingly these levels are markedly 2–10 times lower than what has been reported for EBOV,
 <xref rid="psp412510-bib-0031" ref-type="ref">
  <sup>31</sup>
 </xref> suggesting that favipiravir could also be relevant against these pathogens.
</p>
